 |
 |
From: "PDtrials.org" <[log in to unmask]> To: <[log in to unmask]> Date: Fri, 17 Jun 2005 10:35:41 -0700 Subject: PDtrials.org Bulletin - June 2005 PDtrials.org Bulletin - June 2005 Clinical Trial Information and News for the Parkinson’s Community This email communication provides information on Parkinson’s disease clinical trials that are actively looking for participants, as well as news of interest on research and treatments. In this issue: · Trials Recently Added to PDtrials.org · PDtrials News: Findings on Rasagiline and Ropinirole · Spread the Word About www.PDtrials.org! Trials Recently Added to PDtrials.org see: www.pdtrials.org for more information on any of the following: GenePD The purpose of this trial is to study genetic and other risk factors that may be important in the development of Parkinson’s disease. Study of the Relationship Between Brain Chemical and Mental Function in People with Parkinson’s Disease The goal of this study is to find out how dopamine, a brain chemical, affects memory, reasoning, and other thought processes in people with Parkinson's disease who have dementia, and people with Parkinson’s disease who do not have dementia. Study to Characterize the Genetics of Parkinson’s Disease The goal of this study is to contribute to the understanding of genetics in Parkinson’s disease. In a few cases, Parkinson’s disease appears to be inherited. Parkinson’s disease was noted to have a possible connection to family history as early as 1880. This has led to more recent research on the importance of heredity and Parkinson’s disease. Study of a New Drug, Talampanel, to Treat Uncontrollable Movements (Dyskinesias) This study will test the safety and effectiveness of the drug, Talampanel, to treat the movement symptoms of Parkinson’s disease (PD), including the uncontrollable movements (dyskinesias) that often come about with the long-term use of levodopa. PDTRIALS NEWS Long Term Effectiveness of Ropinirole in Parkinson’s Disease Results from a new 10-year study of patients with Parkinson's disease offer hope to those concerned about the disabling effects of dyskinesias, the uncontrollable, abnormal, jerky body movements that result from long-term l-dopa therapy. Rasagiline Reduces Disability for Patients with Advanced Parkinson's Disease Most patients with established Parkinson's disease receiving long-term treatment with levodopa will eventually have motor fluctuations, defined as periods of the day with poor or absent motor response to their medication (off-time) alternating with periods of clearly improved motor function (on-time). Spread the Word About www.PDtrials.org and the Advancing Parkinson’s Therapies Campaign! If your organization serves the Parkinson’s community, you may wish join forces with us in increasing awareness and education about clinical trials. There are a number of ways to get involved, such as distributing educational materials, featuring an APT booth at a local event, or being listed on the on the Campaign Partners page on PDtrials.org. Please contact us at [log in to unmask] to find out more. APT is led by the Parkinson’s Disease Foundation in collaboration with the American Parkinson Disease Association, the Michael J. Fox Foundation for Parkinson’s Research, the National Parkinson Foundation, the Parkinson’s Action Network, The Parkinson Alliance, and WE MOVE. In addition, APT has a collaborative relationship with the National Institute of Neurological Disorders and Stroke, the Parkinson Study Group, and the Parkinson Pipeline Project. Our success depends on your support. If you know someone who would be interested in receiving information about Parkinson’s clinical research, please forward this email. Subscribe! If you have been forwarded this message and would like to sign-up for regular email updates from PDtrials.org, please go to http://www.pdtrials.org/email_notification.php. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn